GLP-1 receptor agonists reduce the incidence of obesity-associated cancers.
- Current status
- Preliminary signalEvidence unclear · Cancer
- Why
- A large EHR cohort in type 2 diabetes found lower incidence of 10 of 13 obesity-associated cancers versus insulin; versus metformin no cancer was reduced and kidney cancer risk was higher (HR 1.54, 95% CI 1.27-1.87). Observational, susceptible to confounding by indication and surveillance differences; no randomized cancer-outcome data.
- What would change it
- Prespecified cancer outcomes from large RCTs or an active-comparator cohort with negative-control outcomes.
- Linked studies
- 1 · 1 mixed
- Last updated
- Oct 19, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
01The evidence
The evidence, sorted by what it shows
Mixed (1)
- Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 DiabetesRetrospective cohort · 2024 · Study tier 4 · Different population · Benefit
In 1,651,452 US adults with type 2 diabetes, GLP-1 RAs versus insulin were associated with lower risk of 10 of 13 obesity-associated cancers (HRs 0.35 to 0.76) but not postmenopausal breast or thyroid cancer. Versus metformin, no cancer risk was significantly reduced and kidney cancer risk was higher (HR 1.54; 95% CI 1.27-1.87).
02History
How this assessment has changed
- Preliminary signalOct 19, 2026 · Evidence unclear
Owner decision 2026-10-18 on IN-061 (claims audit): recommended options accepted (IN-061.30). Status unchanged; rationale corrected to match the audited links.
- Preliminary signalSep 13, 2026 · Evidence unclear
initial curated status